Regeneus (ASX:RGS), a clinical stage regenerative medicine company focused on the development of cell therapies, announced today that it has received ethics approval for a clinical trial of its new off-the-shelf allogeneic stem cell treatment, known as Progenza, for patients with knee osteoarthritis.
Compumedics Limited (ASX:CMP) is pleased to announce that it has secured a new three-year contract, for the distribution of Compumedics' neurological monitoring systems across provinces in South East China.
Australian biopharmaceutical company Immuron Limited (ASX:IMC) (OTCMKTS:IMROY), manufacturer of Travelan(R), is pleased to announce that it has secured first orders for its Travelan(R) product in the USA.
Organised by the Alliance for Regenerative Medicine (ARM), the 3rd Annual Regenerative Medicine Investor Day was held on March 25th 2015 in New York City.
Compumedics Limited (ASX:CMP) is pleased to announce that the Company's Germany-based, brain blood-flow Doppler-sonography division, Compumedics Germany GmbH, has been awarded a new European patent for a new approach to ultrasound diagnosis and treatment of stroke.
Rhinomed Ltd (ASX:RNO) develops, markets and partners it's internal nasal technology platform into multiple form factors - internal nasal devices.
Regeneus (ASX:RGS) announced today that it has achieved a key manufacturing milestone for its proprietary "off-the-shelf" allogeneic stem cell therapy product, Progenza.
